Home > Clinical Trials
Check All Search

Saved trials

COMPLETED
NCT03734029
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
557 Enrollment(s)
208 Study location(s)
INTERVENTIONAL (PHASE3)
Breast Cancer
RECRUITING
NCT07150208
T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain Metastasis
140 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer With Brain Metastasis


HER2-low Expressing Breast Cancer
RECRUITING
NCT07124000
DESTINY-PANTUMOUR04
100 Enrollment(s)
18 Study location(s)
OBSERVATIONAL (None)
Adenocarcinoma (NOS)


Anal Cancer


Bladder Cancer


Cervical Cancer


Endometrial Cancer


Esophageal Cancer


Gall Bladder Cancer


Gastrointestinal Stromal Tumour


Head and Neck Cancer


Liver Cancer


Melanoma


Mouth Cancer


Nasopharangeal Cancer


Neuroendocrine, Gastrointestinal Cancer


Ovarian Cancer


Pancreatic Cancer


Prostate Cancer


Renal Cell Carcinoma


Salivary Gland Cancer


Sarcoma


Small Cell Lung Cancer


Testicular Cancer


Throat Cancer


Thyroid Cancer


Urethral Cancer


Vaginal Cancer


Vulvar Cancer
RECRUITING
NCT06650501
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
300 Enrollment(s)
3 Study location(s)
INTERVENTIONAL (PHASE4)
Staphylococcus Aureus Endocarditis


Staphylococcus Aureus Septicemia


Staphylococcus Aureus Bacteremia


Staphylococcus Aureus Bloodstream Infection


S. Aureus Bacteremia


S. Aureus Bloodstream Infection
RECRUITING
NCT03661307
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
73 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE1|||PHASE2)
Acute Myeloid Leukemia


Myelodysplastic Syndrome


Recurrent Acute Myeloid Leukemia


Recurrent Myelodysplastic Syndrome


Refractory Acute Myeloid Leukemia
NOT_YET_RECRUITING
NCT07836257
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
28 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Breast Cancer
RECRUITING
NCT07597993
BEYOND Study: A Multicentre, Prospective, Observational Study of Real-world Treatment Patterns and Outcomes of Trastuzumab Deruxtecan in Patients With HR Positive, HER2-low or Ultra-low Metastatic Breast Cancer Previously Treated With Endocrine Therapy
109 Enrollment(s)
9 Study location(s)
OBSERVATIONAL (None)
Breast Cancer
RECRUITING
NCT06253650
Adjuvant TRastuzumab Deruxtecan for HER2-positive Gastroesophageal Cancer With Persistence of miNImal Residual Disease
46 Enrollment(s)
1 Study location(s)
INTERVENTIONAL (PHASE2)
Gastric Cancer


HER2-positive Gastric Cancer